Free Light Chains & Monoclonal Gammopathies
Impact on Diagnostic Panels
With the introduction of Mayo’s expanded serum monoclonal protein panel, which includes quantitation of the kappa and lambda free light chains, urine monoclonal protein studies are no longer required as part of the initial diagnostic screen for monoclonal gammopathies. Dr. Katsmann discusses Mayo’s approach to the diagnosis of monoclonal gammopathies and the use of serum free light chain assays.
- Jerry Katzmann, PhD, from the Division of Clinical Biochemistry and Immunology at Mayo Clinic
Forward to a Colleague
If you have questions, email .